Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 26
1993 82
1994 76
1995 88
1996 144
1997 167
1998 194
1999 164
2000 209
2001 208
2002 183
2003 171
2004 152
2005 186
2006 129
2007 131
2008 136
2009 130
2010 148
2011 154
2012 137
2013 164
2014 166
2015 169
2016 172
2017 147
2018 143
2019 78
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

3,796 results
Results by year
Filters applied: . Clear all
Page 1
A pioneering study: oral clarithromycin treatment for feeding intolerance in very low birth weight preterm infants.
Sancak S, et al. J Matern Fetal Neonatal Med 2018 - Clinical Trial. PMID 28279123
Twenty infants received oral clarithromycin (7.5 mg/kg, twice a day) and 20 control infants did not receive any treatment. RESULTS: Full enteral feeding was attained earlier in the clarithromycin group than in the control group [7 (6-9) versus 9 (9-11) days, respectively; p < .001]. ...We observed no adverse effect of clarithromycin therapy. CONCLUSIONS: Clarithromycin treatment in VLBW preterm infants resulted in better toleration of enteral feeding. ...
Twenty infants received oral clarithromycin (7.5 mg/kg, twice a day) and 20 control infants did not receive any treatment. RESULTS: F …
The Clarithromycin Susceptibility Genotype Affects the Treatment Outcome of Patients with Mycobacterium abscessus Lung Disease.
Guo Q, et al. Antimicrob Agents Chemother 2018. PMID 29483126 Free PMC article.
Clarithromycin susceptibility genotyping offers an alternate, rapid approach to predicting the efficacy of clarithromycin-based antibiotic therapy. ...The results showed that lung disease patients infected with clarithromycin-sensitive and -resistant M. abscessus genotypes differed significantly in clarithromycin-based combination treatment outcomes. ...
Clarithromycin susceptibility genotyping offers an alternate, rapid approach to predicting the efficacy of clarithromycin-base
Role of Clarithromycin in Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
Vora A. J Assoc Physicians India 2017 - Review. PMID 29313589
Clinical studies indicate that long term use of clarithromycin is effective in the treatment of COPD exacerbations with lower incidence of adverse effects. This descriptive review on the role of the clarithromycin in treatment of COPD exacerbations will highlight these properties of clarithromycin in detail....
Clinical studies indicate that long term use of clarithromycin is effective in the treatment of COPD exacerbations with lower inciden …
Aquatic toxicity of the macrolide antibiotic clarithromycin and its metabolites.
Baumann M, et al. Chemosphere 2015. PMID 25051235
Additionally, clarithromycin is partly metabolised to N-desmethyl-clarithromycin, which has no antimicrobial activity. For clarithromycin, some ecotoxicological studies on aquatic organisms have been published. ...Based oncomparable toxicity and similar concentrations of clarithromycin and its active metabolite 14-hydroxy(R)-clarithromycin in surface waters, an additional multiplication factor of 2 to the assessment factor of 10 on the ErC10 of clarithromycin should be used. ...
Additionally, clarithromycin is partly metabolised to N-desmethyl-clarithromycin, which has no antimicrobial activity. For …
A systematic review and meta-analysis of genotypic methods for detecting antibiotic resistance in Helicobacter pylori
Wang YH, et al. Helicobacter 2018 - Review. PMID 29405526
CONCLUSION: The genotypic detection methods were reliable for the diagnosis of clarithromycin and quinolone resistance in the strain and biopsy specimens. The A2142G/C and/or A2143G combination had the best sensitivity and specificity for the detection of clarithromycin resistance....
CONCLUSION: The genotypic detection methods were reliable for the diagnosis of clarithromycin and quinolone resistance in the strain …
Does systemic clarithromycin therapy have an inhibitory effect on tympanosclerosis? An experimental animal study.
Genc G, et al. J Laryngol Otol 2015. PMID 25619629
OBJECTIVE: To demonstrate the inhibitory effects of clarithromycin on in vitro tympanosclerosis. METHOD: Twenty-eight rats were divided into three groups: a clarithromycin group, a non-clarithromycin group and a negative control group. ...Oral clarithromycin therapy was administered in the clarithromycin group. The other groups received no medical treatment. RESULTS: All eardrums in the clarithromycin and non-clarithromycin groups developed myringosclerosis, but there was only one eardrum, in the clarithromycin group, with very severe myringosclerosis. ...
OBJECTIVE: To demonstrate the inhibitory effects of clarithromycin on in vitro tympanosclerosis. METHOD: Twenty-eight rats were divid …
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications
Savarino E, et al. Expert Opin Biol Ther 2019 - Review. PMID 30574820
The authors focus on RHB-104, a novel oral formulation containing a fixed-dose combination of clarithromycin, clofazimine and rifabutin, endowed with synergistic inhibitory activity on MAP strains isolated from CD patients. ...
The authors focus on RHB-104, a novel oral formulation containing a fixed-dose combination of clarithromycin, clofazimine and rifabut …
3,796 results
Jump to page
Feedback